TB-500 news and clinical trials

A review and case report published in Frontiers in oral health examined the use of regenerative peptides like BPC-157, TB-500, and ARA-290 for inferior alveolar nerve injury. The authors reported neurosensory recovery in three clinical cases but cautioned that causality cannot be established.

New review in Missouri medicine: Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.

A narrative review summarized the current evidence on regenerative peptides used for chronic pain management. The authors concluded that clinical evidence in humans remains limited and most of these therapies currently lack FDA approval.

A scoping review concluded that claims regarding peptide supplements for musculoskeletal recovery remain unsubstantiated by current human trials. Authors warned of potential risks including cardiovascular complications.

In a rat study, researchers evaluated the effects of BPC-157 and TB-500 on Achilles tendon healing. Both treatments were associated with improved histopathological parameters and extracellular matrix organization, though the combination of peptides did not provide additional benefits.

New review in Frontiers in aging: Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

The FDA announced a public advisory committee meeting of the Pharmacy Compounding Advisory Committee to seek input on bulk drug substances nominated for the Section 503A bulk drug substances list.

Researchers published a review of approved and unapproved peptide therapies used in sports medicine. They found that while unapproved peptides often show potential for tissue repair in animal models, human safety data remain scarce and carry a risk of serious harm.

Hudson Biotech registered a phase 1/2 trial to evaluate the safety and tolerability of TB-500 in 80 adults with stable atherosclerotic cardiovascular disease. The study aims to explore cardiovascular biomarkers and vascular function.

A review published in the Journal of the American Academy of Orthopaedic Surgeons analyzed the use of therapeutic peptides in orthopaedics. The authors noted that while peptides show promise in preclinical models for tissue regeneration, there is currently a lack of clinical trials.

A narrative review evaluated evidence for injectable peptide therapy in orthopaedic and sports medicine. The authors concluded that current clinical data remain limited or unvalidated for peptides like BPC 157 and others, necessitating further research before clinical use.